Pooled Phase 3 Analysis: Icotyde Improved Joint Pain and Nail Psoriasis in Psoriasis Patients With Self-Reported Psoriatic Arthritis
A post hoc pooled analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 trials, published October 18, 2026 in the Journal of Psoriasis and Psoriatic Arthritis, looked at 216 people with moderate to severe plaque psoriasis who also reported having psoriatic arthritis (149 on Icotyde 200 mg daily, 67 on placebo). At week 16, 47.0% on Icotyde versus 10.7% on placebo reported at least 50% improvement in arthritis disease activity, 45.5% versus 16.1% in arthritis pain, and nail psoriasis scores improved 41.6% on Icotyde while worsening on placebo; side effect rates were similar. The arthritis diagnoses were self-reported and the p-values nominal; dedicated ICONIC-PsA trials are under way.